MMI
MMI develops the Symani Surgical System, a robotic platform enabling open microsurgery on vessels as small as 0.1mm. The company sells its FDA-authorized system, NanoWrist instruments, and proprietary Robotic Suture to academic medical centers and specialty hospitals in 35 countries.
- Company typePrivate
- Founded2015
- HeadquartersPisa, Italy
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What MMI does
MMI (Medical Microinstruments, Inc.) is a privately held medical device company founded in 2015 near Pisa, Italy, and now headquartered in Jacksonville, Florida following a 2022 corporate domicile relocation. The company develops the Symani Surgical System, a robotic platform specifically designed for open microsurgery and microvascular procedures that enables surgeons to operate on anatomical structures as small as 0.1 millimeters in diameter—a precision level not achievable with manual microsurgery or general-purpose surgical robots such as Intuitive Surgical's da Vinci. MMI complements the Symani platform with proprietary NanoWrist instruments (Scissors and Forceps, FDA 510(k) cleared in December 2025), the Synaptix Digital Surgery Platform for visual and workflow enhancements, and the world's first Robotic Suture purpose-built for robotic microsurgery, developed in partnership with Kono Seisakusho (Crownjun).\n\nMMI generates revenue through capital equipment sales of the Symani Surgical System to hospitals and academic medical centers, supplemented by recurring consumables revenue from proprietary instruments and sutures. The company pursues a direct enterprise sales motion in the U.S. and Western Europe and uses exclusive distribution partnerships in Asia-Pacific and Eastern Europe—Gunze Medical Limited for Japan and Synektik Group covering six Eastern European countries. Following FDA authorization for Symani in April 2024, MMI holds regulatory approvals across 35 countries. The establishment of CPT code 1019T and a CMS payment rate for lymphovenous bypass surgery effective January 1, 2026 creates a dedicated reimbursement pathway supporting U.S. hospital adoption.\n\nMMI's commercial strategy is anchored in clinical evidence generation, including FDA-approved IDE studies such as the REMIND trial exploring robotic microsurgical intervention for Alzheimer's disease. The company targets high-acuity microsurgical applications including lymphatic repair, reconstructive surgery, and emerging neurodegenerative disease interventions. With 101–250 employees and approximately $200 million in cumulative funding across a 2022 Series B ($75 million, led by Deerfield) and a 2024 Series C ($110 million, led by Fidelity Management & Research Company), MMI is investing in global commercialization, technology development, and clinical evidence generation.
MMI firmographics
Firmographics- Name
- MMI
- Legal name
- Medical Microinstruments, Inc.
- Website
- https://mmimicro.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- MMI develops the Symani Surgical System, a robotic platform enabling open microsurgery on vessels as small as 0.1mm. The company sells its FDA-authorized system, NanoWrist instruments, and proprietary Robotic Suture to academic medical centers and specialty hospitals in 35 countries.
- Ownership category
- akta.pro rank
MMI industry classification
Industry- Product category
- Surgical Robotics — Microsurgery
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)
- akta.pro secondary industries
- Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity) (HLAHADAE), Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG), Perioperative Supply Chain, Instruments & Surgical Logistics (HLAFAIAO)
Keywords
Where MMI is headquartered
LocationHeadquarters
- HQ city
- Pisa
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
MMI business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Symani Surgical System Hardware Sales: MMI generates revenue from the sale of its Symani Surgical System robotic platform to hospitals and medical centers. The system is commercially available in the US following FDA authorization and CE-marked in Europe.
- Surgical Instruments and Accessories: Revenue from proprietary consumables including NanoWrist instruments and Robotic Suture designed specifically for use with the Symani system.
- Reimbursement for Lymphatic Procedures: Following establishment of CPT code 1019T for lymphovenous bypass surgery and CMS payment rates effective January 2026, hospitals can now submit direct claims for lymphedema treatment procedures using MMI's system, creating reimbursement pathway.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
MMI product offering
Product offeringCore offering
MMI develops and sells the Symani Surgical System, a robotic platform specifically designed for microsurgical procedures, enabling surgeons to operate on vessels as small as 0.1 millimeters in diameter. The system is complemented by proprietary NanoWrist Instruments (Scissors and Forceps) for soft tissue dissection, a purpose-built Robotic Suture developed with Kono Seisakusho (Crownjun), and the Synaptix Digital Surgery Platform for visual enhancements and operating room workflow. The company sells the platform and consumables to hospitals and academic medical centers globally.
Product overview
MMI offers a unified surgical robotics platform centered on the Symani Surgical System, the only commercially available robotic platform in the U.S. designed specifically for reconstructive microsurgery. The platform comprises NanoWrist Instruments (scissors, forceps, and other wristed microsurgical tools) for soft tissue dissection and anastomosis, the Synaptix Digital Surgery Platform providing visual enhancements and workflow efficiencies, and the proprietary Robotic Suture purpose-built for robotic microsurgical procedures. The system enables surgeons to operate on vessels as small as 0.1 millimeters in diameter.
Differentiator
Problem solved
Functional benefit
Brands
- Symani Surgical System: Robotic microsurgery platform with NanoWrist instruments designed for microvascular and microsurgical procedures
- NanoWrist Instruments
- Robotic Suture
- Synaptix Digital Surgery Platform
Products and services
- Symani Surgical System The main robotic surgical platform from MMI, specifically designed for microvascular and microsurgical procedures. FDA-authorized and CE-marked, enabling surgeons to operate on vessels as small as 0.1 millimeters in diameter. Sold to hospitals and academic medical centers for reconstructive microsurgery.
- NanoWrist Scissors and Forceps The world's first fully wristed robotic instruments specifically designed for dissection in open microsurgery. FDA 510(k) cleared for soft tissue dissection, expanding the Symani system's capabilities beyond anastomosis. Consumables used with the Symani Surgical System.
- Robotic Suture The world's first suture purpose-built for robotic microsurgery, developed in partnership with Kono Seisakusho Co., Ltd. (Crownjun). Features shorter length (approximately one-third to one-half of conventional micro sutures), two needle curvature options, and direct surgeon loading capabilities. Targets the $446 million global micro-sutures market.
- Synaptix Digital Surgery Platform The first digital platform built for open microsurgery, enabling visual enhancements and workflow efficiencies in the operating room when used with the Symani Surgical System.
Quantifiable outcome
- Enables surgery on vessels as small as 0.1 millimeters in diameter
- +2 more outcomes
Companies that use MMI
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles1 record
MMI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
MMI partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Gunze Medical LimitedcoreExclusive distribution agreement for Japan, one of the key Asia-Pacific markets. Asia-Pacific represents the fastest growing microsurgery market globally, and this partnership accelerates MMI's regional expansion following regulatory approvals.
- Synektik GroupcorePartnership covering six Eastern European countries, expanding MMI's European market presence beyond existing operations in Italy and other direct markets.
- Kono Seisakusho Co., Ltd. (Crownjun)coreJoint development partnership to create the world's first Robotic Suture purpose-built for the Symani Surgical System. The suture features optimized dimensions and needle configurations for robotic microsurgery, targeting the $446 million global micro-sutures market.
- Leading U.S. and European Research InstitutionscoreMMI is partnering with leading research institutions in the U.S. and Europe for the REMIND clinical study, a first-of-its-kind feasibility study using the Symani Surgical System to perform microsurgical intervention in Alzheimer's patients.
- USF Health and Tampa General HospitalcoreAcademic medical center partnership established during a 2024 trade mission to Italy. USF Health and Tampa General Hospital acquired the Symani Surgical System and began offering robotic microsurgery for lymphedema patients, with Dr. Nicholas Panetta performing lymphatic-venous bypass procedures.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
MMI competitors and assessment
Company assessmentBroad incumbents
- Stryker: Maker of the Mako robotic-arm assisted surgery system, primarily for orthopedic procedures. While not a direct microsurgery competitor, Stryker is a relevant surgical robotics incumbent with the resources to enter adjacent specialties.
- Zimmer Biomet: Developer of the ROSA robotic system for neurosurgery, spine, and orthopedics. Comparable as a surgical robotics incumbent operating in adjacent high-precision surgical niches that overlap with MMI's microsurgical focus.
- Smith+Nephew: Maker of the CORI handheld robotic-assisted surgery system for orthopedics. Relevant as a diversified medtech incumbent with robotics capabilities and global commercial reach overlapping with MMI's hospital customer base.
- Globus Medical: Spine and orthopedic robotics company (ExcelsiusGPS) and one of the top three autonomous robotic surgery patent assignees alongside MMI. Comparable as a high-precision surgical robotics incumbent with overlapping IP positioning.
- Medtronic: Developer of the Hugo robotic-assisted surgery platform. As a diversified medical device leader, Medtronic competes broadly with MMI in surgical robotics and possesses the scale and capital to expand into microsurgical indications.
- Johnson & Johnson (Ethicon / Auris Health): Owner of the MONARCH platform and developer of the Ottava robotic surgery system. J&J's medtech scale and R&D capacity position it as a strategic competitor that could extend into microsurgical robotics over time.
- Intuitive Surgical: Maker of the da Vinci surgical robotic system, the dominant incumbent in robotic surgery. While da Vinci focuses on larger-scale laparoscopic procedures rather than sub-millimeter microsurgery, it is the principal competitive reference point and potential disruptor for MMI's robotic surgery platform.
Direct peers
- Corindus (Siemens Healthineers): Developer of the CorPath GRX robotic system for vascular interventions. Closely comparable as a niche surgical robotics platform targeting precision catheter-based procedures rather than broad laparoscopic surgery.
Emerging players
- Penumbra: Developer of the REAL Robotic System for peripheral vascular interventions. Comparable as an emerging robotics player focused on vascular and specialty surgical applications adjacent to MMI's microsurgical niche.
- Moon Surgical: A French-based emerging surgical robotics company developing the Maestro system for laparoscopic soft tissue surgery. Comparable as a venture-backed European surgical robotics peer pursuing a category-positioning strategy similar to MMI's.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MMI social profiles
Digital presenceMMI financial estimates
Financial estimateRevenue estimate
Valuation estimate
MMI leadership team
Management profileNumber of profiles
Profiles6 records
MMI funding detail
Funding detailFunding overview
Funding rounds4 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MMI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MMI
What does MMI do?
MMI develops and sells the Symani Surgical System, a robotic platform specifically designed for microsurgical procedures, enabling surgeons to operate on vessels as small as 0.1 millimeters in diameter. The system is complemented by proprietary NanoWrist Instruments (Scissors and Forceps) for soft tissue dissection, a purpose-built Robotic Suture developed with Kono Seisakusho (Crownjun), and the Synaptix Digital Surgery Platform for visual enhancements and operating room workflow. The company sells the platform and consumables to hospitals and academic medical centers globally.
Is MMI a public or private company?
MMI is a private company. It is classified as venture growth investor backed and is currently operating.
When was MMI founded?
MMI was founded in 2015. It employs 251 to 500 people.
Where is MMI based?
MMI is headquartered in Pisa, Italy, in the Europe region.
How does MMI make money?
Three revenue lines are on record. Symani Surgical System Hardware Sales are the primary driver. The others are surgical Instruments and Accessories and reimbursement for Lymphatic Procedures.
Who are MMI's main competitors?
Broad incumbents on record are Stryker, Zimmer Biomet, Smith+Nephew, Globus Medical, Medtronic, Johnson & Johnson (Ethicon / Auris Health) and Intuitive Surgical. Corindus (Siemens Healthineers) is listed as a direct peer. Emerging players are Penumbra and Moon Surgical.
Does MMI have an API?
No public API is recorded for MMI.
What industry is MMI in?
MMI's product category is Surgical Robotics — Microsurgery. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAE, Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity). Its NAICS code is 339112 and its SIC code is 3841.